ELI LILLY & Co

LLYSEC EDGAR

Pharmaceutical Preparations(IN)CIK: 59478

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenues	$34.1B	$28.5B	$28.3B	$24.5B	$22.3B
Cost of Goods and Services Sold	$7.1B	$6.6B	$7.3B	$5.5B	$4.7B
Research and Development Expense	—	—	—	$6.0B	$5.6B
Selling, General and Administrative Expense	$7.4B	$6.4B	$6.4B	$6.1B	$6.2B
Operating Expenses	—	—	—	—	—
Interest Expense	—	—	$339.8M	$359.6M	$400.6M
Nonoperating Income (Expense)	$97.0M	-$320.9M	-$201.6M	$1.2B	$291.6M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$78.7B	$64.0B	$49.5B	$48.8B	$46.6B
Assets, Current	$32.7B	$25.7B	$18.0B	$18.5B	$17.5B
Cash and Cash Equivalents, at Carrying Value	$3.3B	$2.8B	$2.1B	$3.8B	$3.7B
Accounts Receivable, after Allowance for Credit Loss, Current	$11.0B	$9.1B	$6.9B	$6.7B	$5.9B
Inventory, Net	$7.6B	$5.8B	$4.3B	$3.9B	$4.0B
Liabilities, Current	$28.4B	$27.3B	$17.1B	$15.1B	$12.5B
Long-term Debt	—	$19.1B	$14.8B	$16.7B

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$4.2B	$7.6B	$7.4B	$6.5B	$4.8B
Net Cash Provided by (Used in) Investing Activities	-$7.2B	-$3.8B	-$2.9B	-$2.3B	-$8.1B
Net Cash Provided by (Used in) Financing Activities	$3.5B	-$5.4B	-$4.1B	-$3.1B	-$2.3B
Payments of Dividends	$4.1B	$3.5B	$3.1B	$2.7B	$2.4B
Payments for Repurchase of Common Stock	$750.0M	$1.5B	$1.3B	$500.0M	$4.4B

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)